网站地图
首页 > CSCO动态 > Special Issue ESMO 2017 report!

Special Issue ESMO 2017 report!

作者: 来源: 发布时间:2017-11-08 08:01:14 今日访问/总访问:2|71

The 2017 ESMO report contains the latest updates in lung cancer regarding clinical management and cancer research that were presented at the European Society for Medical Oncology (ESMO) 2017 annual meeting, that took place in September, Spain fromSeptember 8th – 12th, 2017.

Highlights include the latest clinical trial results for the PD-L1 inhibitors atezolizumab anddurvalumab, new data for the PD-1 inhibitor nivolumab and the toll-like receptor 9 agonist lefitolimod; a discussion of the optimal succession of targeted agents across several treatment lines for both EGFR and ALK positive disease; positive data for combined dabrafenib/trametinib therapy for BRAF-positive lung cancer patients; and lots more.

The memo Special Issue report is produced by Springer, as a supplement of memo (the Magazine of European Medical Oncology), and sponsored by Boehringer Ingelheim. For more information on the memo inOncology Special Issue series, and for free access to all previous editions, visit the memo-inOncologywebsite.

Download the full report (English)

Download the full report (Chinese)